Key facts
- This page summarizes Jan van den Bossche's Form 4 filing for IMMUNIC, INC. (IMUX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2022, 21:30.
Jan van den Bossche - 15 Jun 2022 Form 4 Insider Report for IMMUNIC, INC. (IMUX)
- Reporting relationship
- Director
- Issuer ticker
- IMUX
- Reported as of
- 15 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2022, 21:30:58 UTC
- Prior SEC filing
- 14 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jan van den Bossche
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jan van den Bossche filed Form 4 for IMMUNIC, INC. (IMUX) on 17 Jun 2022.
Change
- Previous filing in this sequence was filed on 14 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMUX
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 15 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $3.40
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in monthly increments over a period of one year from the grant date.